Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.41 |
| ▸ | CTPS1 | P17812 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869249 | 0.85 | AAK1 (0.48) | AAK1HDAC3HDAC1HDAC2CYP17A1 | |
| SCHEMBL29530597 | 0.82 | AAK1 (0.52) | AAK1HDAC3HDAC1HDAC2CYP17A1 | |
| SCHEMBL2133767 | 0.82 | AAK1 (0.52) | AAK1HDAC3HDAC1HDAC2CYP17A1 | |
| SCHEMBL5868960 | 0.82 | AAK1 (0.68) | AAK1HDAC3HDAC1HDAC2CYP17A1 | |
| SCHEMBL30058636 | 0.82 | AAK1 (0.68) | AAK1HDAC3HDAC1HDAC2CYP17A1 | |
| SCHEMBL15522475 | 0.81 | HDAC2 (0.55) | AAK1HDAC3HDAC1HDAC2PORCN | |
| SCHEMBL25214140 | 0.81 | AAK1 (0.51) | AAK1HDAC1CYP17A1MAP4K4ABL1 | |
| SCHEMBL25256959 | 0.81 | AAK1 (0.54) | AAK1CYP17A1MAP4K4ABL1 | |
| SCHEMBL27039833 | 0.80 | PORCN (0.50) | AAK1PORCNABL1 | |
| SCHEMBL25214050 | 0.79 | AAK1 (0.46) | AAK1HDAC3HDAC1HDAC2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | AAK1 1755/4885HDAC3 7/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.